S Shackelford Pharma

Waren und Dienstleistungen

05 Medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids; medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, medicinal compounds containing cannabis, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Medicinal herbal extracts for treating disease; Medicinal herbal extracts for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, medical cannabis and marijuana extracts for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbal preparations; medicinal herbal preparations for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely marijuana preparations, cannabis dried flowers and concentrates for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Marijuana derivatives, natural cannabinoids, and synthetic cannabinoids used for treating medical conditions; Marijuana derivatives, natural cannabinoids, and synthetic cannabinoids used for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, managing the effects of chemotherapy, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely liquids, oils, oral sprays, pills, capsules, creams, tinctures, lotions, suppositories, and baked medicinal goods for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbs for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; medicinal herbs in dried or preserved form for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely medical marijuana and cannabis for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; pills, capsules, infused with cannabis, medical marijuana, natural cannabinoids, or synthetic cannabinoids; extracts and derivatives of cannabis, medical marijuana, natural cannabinoids, and synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, salves, concentrates, pastes, extracts, tinctures, marijuana clones, cannabis clones, tissue cultures, powders, juice, resins, oils, and tetrahydrocannabinol (THC) for treating diseases and medical conditions classified as "orphan" by the US food and drug administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; suppositories infused with cannabis, medical marijuana, natural cannabinoids, cannabis derivatives, or synthetic cannabinoids; Suppositories infused with cannabis, medical marijuana, cannabis derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; transdermal patches infused with cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids; Transdermal patches infused with cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Cannabis, cannabinoids, and medical marijuana based petfoods and medications; Cannabis, cannabinoids, and medical marijuana based pet foods and medications for treating pets for veterinary conditions; edible oils and edible butters containing cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids; Edible oils and edible butters containing cannabis, medical marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids for treating headaches, neurodegeneration, neurogenesis, epilepsy, childhood epilepsy, paediatric encephalopathies, pain, cancer, managing the effects of chemotherapy, Tourette Syndrome, post-traumatic stress disorder (PTSD), nausea, vomiting, premenstrual syndrome (PMS), neurologic conditions, sleep disorders, cognitive decline, facial pain, spasms, gastrointestinal diseases, rare diseases, Alzheimer's disease, appetite loss, cancer, Crohn's disease, anorexia, bulimia, epilepsy, glaucoma, schizophrenia, multiple sclerosis, muscle spasms, nausea, pain, headaches, wasting syndrome (cachexia), and diseases classified as "orphan" by the US Food and Drug Administration, namely, Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related epileptic encephalopathy, SCN8A related epileptic encephalopathy, Electrical status epilepticus in sleep (ESES), Landau-Kleffner syndrome, Continuous spikes and waves during sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome, SYNGAP related epileptic encephalopathy, Fragile X Syndrome, epilepsy with focal cortical dysplasia type II, KCNT1 related epileptic encephalopathy, SCN2A related epileptic encephalopathy, STXBP1 related epileptic encephalopathy, KAND KIF1A related epileptic encephalopathy, HNRNPH2 related epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman Syndrome, Established Status Epilepticus, Refractory Status Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant mesial temporal lobe epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign Rolandic epilepsy or benign childhood epilepsy with centrotemporal spikes (BCECTS), Epilepsy with myoclonic absences, Childhood absence epilepsy (CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos syndrome, Benign Occipital Epilepsy, Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic epilepsy in infancy, Myoclonic astatic epilepsy (MAE), Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI Seizures, Focal Seizures, Generalized onset Seizures, Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy, Automatism Epilepsy, Catamenial epilepsy, Epilepsia partialis continua, Febrile infection-related epilepsy syndrome (FIRES), Migralepsy, Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg disease (abbreviated ULD or EPM1), Vertiginous epilepsy; Cannabis, medical marijuana, marijuana plant derivatives, natural cannabinoids, or synthetic cannabinoids - infused foods for medical purposes, namely, frozen foods, treats, desserts, baked goods, desserts, grain based bars, cakes, cereal bars, cookies, brownies, muffins, cupcakes, chocolate, chocolate confectionery, sugar confectionery, candies, gum, jellies, biscuits, ice cream, sorbet, and frozen bars; beverages infused with medical cannabis, medical marijuana, medical marijuana plant derivatives, medical natural cannabinoids, or medical synthetic cannabinoids

35 Providing information to the public in the field of medical cannabis and its use in the treatment of medical conditions

40 Manufacturing medical cannabis compounds to the order and specification of others; manufacturing products that contain medical cannabis compounds to the order and specification of others

42 Research, development and formulation services in the field of medical cannabis compounds to the order and specification of others; research, development and formulation services in the field of products that contain medical cannabis compounds to the order and specification of others; providing information to the public in the field of research in the field of medical marijuana

44 Providing information to the public via an Internet website in the field of pharmaceutical advice concerning medical cannabis and its use in the treatment of medical conditions

Übersetzung anzeigen

Markenform	Bildmarke
Aktenzeichen	1674567
Länder
Basismarke	Nr. 2098683, 09. April 2021

Anmeldedatum	13. September 2021
Ablaufdatum	13. September 2031

Datum	Belegnummer	Bereich	Eintrag
08. Juni 2023	2023/23 Gaz	JP	Ablehnung
24. Januar 2023	2023/4 Gaz	AU	RAW: Rule 18ter(2)(ii) GP following a provisional refusal
09. September 2022	2022/38 Gaz	EM	Ablehnung
02. August 2022	2022/32 Gaz	AU	Ablehnung
13. September 2021		CA	Eintragung

Schützen Sie diese Marke vor Nachahmern!

Markendetails Letztes Update: 12. Juni 2023

Markeninhaber

Markenvertreter

Waren und Dienstleistungen

Markenhistorie